<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03736980</url>
  </required_header>
  <id_info>
    <org_study_id>124</org_study_id>
    <nct_id>NCT03736980</nct_id>
  </id_info>
  <brief_title>Beyond the Self and Back: Neuropharmacological Mechanisms Underlying the Dissolution of the Self</brief_title>
  <official_title>Beyond the Self and Back: Neuropharmacological Mechanisms Underlying the Dissolution of the Self</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to identify neural signatures, behavioral and phenomenological&#xD;
      expressions of self-related processes including: sense of agency, semantic distinction&#xD;
      between self and other, selflessness (altruism), social agency, embodied self&#xD;
      (interoception), perceptual functioning of dissolved self including hallucinations and&#xD;
      crossmodal processing, and finally the mystical type dissolution of the self.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Four placebo-controlled, double blind sets of procedures using psilocybin with four&#xD;
      independent study groups will be conducted. The number of subjects, testing procedures and&#xD;
      dose of psilocybin for each group are as follows: group 1 (20 subjects, EEG, questionnaires,&#xD;
      0.200 mg/Kg body weight), group 2 (30 subjects, functional magnetic resonance imaging (fMRI),&#xD;
      questionnaires, 0.200 mg/Kg body weight), group 3 (10 subjects, fMRI, questionnaires, 0.215&#xD;
      mg/Kg body weight), study group 4 (80 subjects, blood serum and saliva parameters,&#xD;
      questionnaires, fMRI (only in 20 subjects from this group), 0.315 mg/Kg body weight). The&#xD;
      groups 1, 2 and 3 involve healthy volunteers. The group 4 involves healthy volunteer&#xD;
      long-term and short-term meditators during a 5-day group meditation retreat. Together, 140&#xD;
      subjects will participate in the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2013</start_date>
  <completion_date type="Actual">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Four independent study groups</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>fMRI resting state activity (BOLD signal)</measure>
    <time_frame>60 minutes</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>EEG measurement (ERPs)</measure>
    <time_frame>60 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjective effects will be assessed with the 5-Dimensional Altered States of Consciousness Rating Scale (5D-ASC)</measure>
    <time_frame>7 hours</time_frame>
    <description>Total score of the 5D-ASC (5-Dimensional Altered States of Consciousness Rating Scale). Consists of 94 items which are rated on a visual analogue scale (100 millimeters in length). The scale ranges from 0 (no alterations) to 100 (maximum alterations). The items are scored by measuring the millimeters from the low end of the scale to the participant's mark (from 0 to 100).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mood changes will be assessed with the Positive and Negative Affect Schedule (PANAS)</measure>
    <time_frame>7 hours</time_frame>
    <description>The Positive and Negative Affect Schedule (PANAS) is a self-report questionnaire that consists of 10 positive and 10 negative valence word items. Each item is rated on a 5-point likert scale with a range from 1 (not at all) to 5 (very much). The final score of the PANAS Scale is the sum of the 10 terms on the positive scale in which a higher score indicates increased positive affect, with a subscale range of 10 to 50 and the sum of the 10 terms on the negative scale in which a higher score indicates more negative affect, with a subscale range of 10 to 50.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Psilocybin Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1: randomized, placebo-controlled, double-blind, cross-over design</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Psilocybin Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 2: randomized, placebo-controlled, double-blind, cross-over design</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Psilocybin Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 3: randomized, placebo-controlled, double-blind, cross-over design</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Psilocybin Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 4: randomized, placebo-controlled, double-blind, matched group design</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>100% lactose</description>
    <arm_group_label>Psilocybin Group 1</arm_group_label>
    <arm_group_label>Psilocybin Group 2</arm_group_label>
    <arm_group_label>Psilocybin Group 3</arm_group_label>
    <arm_group_label>Psilocybin Group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Psilocybine</intervention_name>
    <description>Study Group 1: 0.250 mg/Kg weight Study Group 2: 0.200 mg/Kg body weight Study Group 3: 0.215 mg/Kg body weight Study Group 4: 0.315 mg/Kg body weight</description>
    <arm_group_label>Psilocybin Group 1</arm_group_label>
    <arm_group_label>Psilocybin Group 2</arm_group_label>
    <arm_group_label>Psilocybin Group 3</arm_group_label>
    <arm_group_label>Psilocybin Group 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male and female volunteers at the age of 20-40 y (Group 1, 2 and 3) and 20-60&#xD;
             y (Group 4)&#xD;
&#xD;
          -  Willing and capable to give informed consent for the participation in the study after&#xD;
             it has been thoroughly explained&#xD;
&#xD;
          -  Willing to refrain from drinking alcohol the day before testing session, from drinking&#xD;
             alcohol and caffeinated drinks at the testing days and from consuming psychoactive&#xD;
             substances 2 weeks before testing days and for the duration of the study.&#xD;
&#xD;
          -  Able and willing to comply with all study requirements&#xD;
&#xD;
          -  Informed consent form was signed&#xD;
&#xD;
        Further inclusion criteria for the Study Group 4:&#xD;
&#xD;
          -  over 5000 hours of meditation experience (40 participants)&#xD;
&#xD;
          -  meditation naive (with no experience in meditation) or with a low experience in&#xD;
             meditation (as a criterium the total amount of less than &lt;100 hours of meditation&#xD;
             experience will be used) (40 participants)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Poor knowledge of the German language&#xD;
&#xD;
          -  Previous significant adverse response to a hallucinogenic drug&#xD;
&#xD;
          -  Participation in another study where pharmaceutical compounds will be given&#xD;
&#xD;
          -  Self or first-degree relatives with present or antecedent psychiatric disorders&#xD;
&#xD;
          -  History of head trauma or fainting&#xD;
&#xD;
          -  Recent cardiac or brain surgery&#xD;
&#xD;
          -  Current use of medication known to affect brain function (e.g. benzodiazepines,&#xD;
             antihistamines, aspirin, beta blockers, theophylline, azetazolamide, etc.)&#xD;
&#xD;
          -  Concomitant therapy with potent inhibitors of cytochrome P-450 isoenzyme 3A4 (HIV&#xD;
             protease inhibitors, macrolide antibiotics, azolederivative anti-infective agents)&#xD;
&#xD;
          -  Presence of major internal or neurological disorders (including sepsis,&#xD;
             pheochromocytoma, thyrotoxicosis, drug-induced fibrosis, familiar or basilar artery&#xD;
             migraine)&#xD;
&#xD;
          -  Cardiovascular disease (hypertonia, coronary artery disease, heart insufficiency,&#xD;
             myocardial infarction within the past 6 months, coronary spastic angina)&#xD;
&#xD;
          -  Peripheral vascular disease (thromboangiitis obliterans, luetic arteritis, severe&#xD;
             arteriosclerosis, thrombophlebitis, Raynaud's disease)&#xD;
&#xD;
          -  Liver or renal disease&#xD;
&#xD;
          -  Pregnant or breastfeeding women (a urine pregnancy test will be done for all women&#xD;
             capable of bearing children)&#xD;
&#xD;
          -  Women of childbearing potential who are not using effective, established&#xD;
             contraception, such as oral, injected or implanted hormonal methods of contraception,&#xD;
             placement of an intrauterine device (IUD) or intrauterine system (IUS), barrier&#xD;
             methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps)&#xD;
             with spermicidal foam/gel/film/cream/suppository&#xD;
&#xD;
        Further exclusion criteria for the Study Group 2, 3 and 4:&#xD;
&#xD;
          -  Inability to lie still for about 60 minutes (e.g. because of sneezing, itching,&#xD;
             tremor, pain)&#xD;
&#xD;
          -  Metal parts in the body (piercings, brain aneurysm clip, implanted neural&#xD;
             stimulator/cardiac pacemaker/defibrillator/Swan Ganz catheter/insulin pump, cochlear&#xD;
             implant); metal shrapnel or bullet, ocular foreign body (e.g. metal shavings); current&#xD;
             or previous job in metalworking industry&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
        The presence of any one of the above mentioned exclusion criteria will lead to exclusion of&#xD;
        the subject.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 11, 2018</study_first_submitted>
  <study_first_submitted_qc>November 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2018</study_first_posted>
  <last_update_submitted>November 3, 2020</last_update_submitted>
  <last_update_submitted_qc>November 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psilocybin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

